XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities        
Net (loss) income $ (181,223) $ 29,403 $ (84,134)  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities        
Loss (gain) from Continuation Advances 52,000 (34,000) (18,000)  
Depreciation 7,199 6,428 7,265 $ 7,300
Amortization of intangible assets 381      
Amortization of right-of-use assets 4,005 2,876 2,683  
Amortization of debt discount and financing costs 539 129 1,212  
Stock-based compensation 73,355 17,533 16,401  
Loss from derivative     (16)  
Amortization (accretion) from investment premium (discount) 4,011 (107) (913)  
Change in the estimated fair value of contingent consideration 1,143      
Loss on disposition of equipment 54   194  
Deferred income taxes (93,649)      
Changes in assets and liabilities        
Accounts receivable (7,166) (1,603) (6,671)  
Inventory (12,431) (1,096) 3,915  
Prepaid expenses and other assets (1,024) (1,063) (523)  
Accounts payable 6,363 (5,072) 1,713  
Accrued expenses 15,320 4,102 2,333  
Deferred revenue 25,736 729 2,134  
Operating lease liabilities (4,990) (3,802) (3,428)  
Other liabilities (803) 5,046 (2,477)  
Net cash (used in) provided by operating activities (111,180) 19,503 (78,312)  
Cash flows from investing activities        
Purchase of property and equipment (5,931) (1,039) (2,836)  
Purchase of investments (988,046) (373,283) (57,727)  
Sales of investments 212,734 1,400 1,500  
Maturities of investments 422,505 153,600 121,110  
Net cash (used in) provided by in investing activities (678,531) (219,322) 62,047  
Cash flows from financing activities        
Continuation Advances (52,000) 34,000 18,000  
Notes payable principal payoff (361) (16,000)    
Proceeds from issuance of Convertible Senior Notes, net of issuance costs 895,536      
Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs 294,845 187,479    
Proceeds from issuance of common stock from equity plans 31,806 46,360 8,548  
Other (245)      
Net cash provided by financing activities 1,169,581 251,839 26,548  
Net increase in cash and cash equivalents and restricted cash 379,870 52,020 10,283  
Cash and cash equivalents and restricted cash at beginning of period 85,947 33,927 33,927 23,644
Cash and cash equivalents and restricted cash at end of period 465,817 85,947 33,927 $ 33,927
Cash and cash equivalents at end of period 460,725 81,611 29,627  
Restricted cash at end of period 5,092 4,336 4,300  
Supplemental disclosure of cash flow information        
Interest paid 6,928 491 1,400  
Supplemental disclosure of non-cash investing and financing activities        
Inventory transferred to property and equipment 2,586 1,097 2,062  
Property and equipment transferred to inventory (383) $ (919) $ (1,536)  
Right-of-use asset and liability additions and modifications 2,576      
Issuance of common stock in acquisition of Omniome 237,885      
Circulomics, Inc [Member]        
Cash flows from investing activities        
Cash paid for purchase of business acquisition, net of cash acquired (28,560)      
Omniome, Inc [Member]        
Cash flows from investing activities        
Cash paid for purchase of business acquisition, net of cash acquired $ (291,233)